Molecular Partners AG

Molecular Partners AG - Enterprise Valueverified

MLLCF

Price:

$3.8

Market Cap:

$123.04M

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x co...[Read more]

Industry

Biotechnology

IPO Date

2018-06-14

Stock Exchange

OTC

Ticker

MLLCF

The Enterprise Value as of August 2026 (TTM) for Molecular Partners AG (MLLCF) is 62.13M

According to Molecular Partners AG’s latest financial reports and current stock price. The company's current Enterprise Value is 62.13M. This represents a change of 61.49% compared to the average of 38.47M of the last 4 quarters.

Molecular Partners AG (MLLCF) Historical Enterprise Value (quarterly & annually)

How has MLLCF Enterprise Value performed in the past?

The mean historical Enterprise Value of Molecular Partners AG over the last ten years is 253.37M. The current 62.13M Enterprise Value has changed 2.35% with respect to the historical average. Over the past ten years (40 quarters), MLLCF's Enterprise Value was at its highest in in the September 2016 quarter at 706.35M. The Enterprise Value was at its lowest in in the December 2023 quarter at -70218218.32.

Quarterly (TTM)
Annual

Average

253.37M

Median

295.21M

Minimum

47.34M

Maximum

486.74M

Molecular Partners AG (MLLCF) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Molecular Partners AG Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 56.38%

Maximum Annual Enterprise Value = 486.74M

Minimum Annual Increase = -75.98%

Minimum Annual Enterprise Value = 47.34M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202547.34M-38.31%
202476.74M56.38%
202349.07M-58.03%
2022116.92M-75.98%
2021486.74M24.09%
2020392.26M29.89%
2019302.00M4.71%
2018288.42M-30.89%
2017417.35M16.95%
2016356.87M-26.95%

Molecular Partners AG (MLLCF) Average Enterprise Value

How has MLLCF Enterprise Value performed in the past?

The current Enterprise Value of Molecular Partners AG (MLLCF) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

57.72M

5-year avg

155.36M

10-year avg

253.37M

Molecular Partners AG (MLLCF) Enterprise Value vs. Peers

How is MLLCF’s Enterprise Value compared to its peers?

Molecular Partners AG’s Enterprise Value is greater than Botanix Pharmaceuticals Limited (40.90M), less than Innate Pharma S.A. (138.53M), less than NDT Pharmaceuticals Inc. (88.37M), greater than Brii Biosciences Limited (-29305211.45), less than Scancell Holdings plc (108.69M), less than JW (Cayman) Therapeutics Co. Ltd (328.68M), less than NervGen Pharma Corp. (385.88M), less than Ascend Wellness Holdings, Inc. (648.27M), less than Santhera Pharmaceuticals Holding AG (296.91M), less than Hofseth BioCare ASA (844.63M),

Build a custom stock screener for Molecular Partners AG (MLLCF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Molecular Partners AG using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Molecular Partners AG (MLLCF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Molecular Partners AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Molecular Partners AG's Enterprise Value?

What is the highest Enterprise Value for Molecular Partners AG (MLLCF)?

What is the 3-year average Enterprise Value for Molecular Partners AG (MLLCF)?

What is the 5-year average Enterprise Value for Molecular Partners AG (MLLCF)?

How does the current Enterprise Value for Molecular Partners AG (MLLCF) compare to its historical average?